拉米普利特对人脐血-间充质干细胞衍生分泌组增强内皮祖细胞迁移的影响

Proceedings of the 2020 7th International Conference on Biomedical and Bioinformatics Engineering Pub Date : 2020-11-06 DOI:10.1145/3444884.3444914

Y. Oktaviono, I. A. Isaridha, F. Sandra, A. Lefi, A. Subagjo

{"title":"拉米普利特对人脐血-间充质干细胞衍生分泌组增强内皮祖细胞迁移的影响","authors":"Y. Oktaviono, I. A. Isaridha, F. Sandra, A. Lefi, A. Subagjo","doi":"10.1145/3444884.3444914","DOIUrl":null,"url":null,"abstract":"Endothelial progenitor cells (EPCs) have a critical role in angiogenesis and vasculogenesis of coronary artery disease (CAD) patients. Secretome of human Umbilical Cord Blood-Mesenchymal Stem Cell (hUCB-MSCs) can promote neovascularization. Ramiprilat is an active metabolite of ramipril that has shown benefit in cardiovascular disease. The effect of hUCB-MSCs-derived secretome alone or combination with ramiprilat on EPCs migration is not yet elucidated. This study aimed to identify the effect of hUCB- MSC derived secretome and its combination with ramiprilat on EPCs migration. EPCs were collected from peripheral blood of CAD patient and cultured in the Stemline II medium. Cultured EPCs were then divided into groups of control, ramiprilat 10 μmol, hUCB-MSCs derived secretome (2%, 10%, and 20%), and its combination. The migration of EPCs was assessed using a Boyden chamber assay. Ramiprilat and hUCB-MSCs-derived secretome at all doses increase EPCs migration in dose-dependent manner. Combination of hUCB-MSCs-derived secretome at dose 10% and 20% and ramiprilat significantly increase migrated cells compared to ramiprilat only and secretome only group (p<0.001). In conclusion, hUCB-MSCs-derived secretome and ramiprilat enhance EPCs migration and combination of those two substances furtherly increased the migrated cells. hUCB-MSCs-derived secretome has the potential as regenerative treatment for CAD patients.","PeriodicalId":142206,"journal":{"name":"Proceedings of the 2020 7th International Conference on Biomedical and Bioinformatics Engineering","volume":"1 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2020-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Ramiprilat Effects on Endothelial Progenitor Cells Migration is Increased by Human Umbilical Cord Blood-Mesenchymal Stem Cells derived Secretome\",\"authors\":\"Y. Oktaviono, I. A. Isaridha, F. Sandra, A. Lefi, A. Subagjo\",\"doi\":\"10.1145/3444884.3444914\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Endothelial progenitor cells (EPCs) have a critical role in angiogenesis and vasculogenesis of coronary artery disease (CAD) patients. Secretome of human Umbilical Cord Blood-Mesenchymal Stem Cell (hUCB-MSCs) can promote neovascularization. Ramiprilat is an active metabolite of ramipril that has shown benefit in cardiovascular disease. The effect of hUCB-MSCs-derived secretome alone or combination with ramiprilat on EPCs migration is not yet elucidated. This study aimed to identify the effect of hUCB- MSC derived secretome and its combination with ramiprilat on EPCs migration. EPCs were collected from peripheral blood of CAD patient and cultured in the Stemline II medium. Cultured EPCs were then divided into groups of control, ramiprilat 10 μmol, hUCB-MSCs derived secretome (2%, 10%, and 20%), and its combination. The migration of EPCs was assessed using a Boyden chamber assay. Ramiprilat and hUCB-MSCs-derived secretome at all doses increase EPCs migration in dose-dependent manner. Combination of hUCB-MSCs-derived secretome at dose 10% and 20% and ramiprilat significantly increase migrated cells compared to ramiprilat only and secretome only group (p<0.001). In conclusion, hUCB-MSCs-derived secretome and ramiprilat enhance EPCs migration and combination of those two substances furtherly increased the migrated cells. hUCB-MSCs-derived secretome has the potential as regenerative treatment for CAD patients.\",\"PeriodicalId\":142206,\"journal\":{\"name\":\"Proceedings of the 2020 7th International Conference on Biomedical and Bioinformatics Engineering\",\"volume\":\"1 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-11-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Proceedings of the 2020 7th International Conference on Biomedical and Bioinformatics Engineering\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1145/3444884.3444914\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Proceedings of the 2020 7th International Conference on Biomedical and Bioinformatics Engineering","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1145/3444884.3444914","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

内皮祖细胞(EPCs)在冠状动脉疾病(CAD)患者的血管生成和血管生成中起着关键作用。人脐血-间充质干细胞(hub - mscs)分泌组可促进新生血管的形成。雷米普利是雷米普利的一种活性代谢物，已显示对心血管疾病有益。hub - mscs衍生的分泌组单独或联合雷米普利特对EPCs迁移的影响尚不清楚。本研究旨在确定hub - MSC衍生分泌组及其与雷米普利特联合对EPCs迁移的影响。从CAD患者外周血中收集EPCs，在Stemline II培养基中培养。将培养的EPCs分为对照组、雷米普利特10 μmol组、hub - mscs衍生分泌组(2%、10%、20%)组和其联合组。EPCs的迁移使用博伊登腔法进行评估。拉米普利特和hub - mscs衍生的分泌组在所有剂量下都以剂量依赖的方式增加EPCs的迁移。与仅雷米普利特组和仅雷米普利特组相比，10%和20%剂量的hub - mscs衍生分泌组与雷米普利特组联合使用显著增加了迁移细胞(p<0.001)。综上所述，hub - mscs衍生的分泌组和雷米普利特促进了EPCs的迁移，两者联合使用进一步增加了迁移细胞的数量。hub - mscs衍生的分泌组具有作为CAD患者再生治疗的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Ramiprilat Effects on Endothelial Progenitor Cells Migration is Increased by Human Umbilical Cord Blood-Mesenchymal Stem Cells derived Secretome

Endothelial progenitor cells (EPCs) have a critical role in angiogenesis and vasculogenesis of coronary artery disease (CAD) patients. Secretome of human Umbilical Cord Blood-Mesenchymal Stem Cell (hUCB-MSCs) can promote neovascularization. Ramiprilat is an active metabolite of ramipril that has shown benefit in cardiovascular disease. The effect of hUCB-MSCs-derived secretome alone or combination with ramiprilat on EPCs migration is not yet elucidated. This study aimed to identify the effect of hUCB- MSC derived secretome and its combination with ramiprilat on EPCs migration. EPCs were collected from peripheral blood of CAD patient and cultured in the Stemline II medium. Cultured EPCs were then divided into groups of control, ramiprilat 10 μmol, hUCB-MSCs derived secretome (2%, 10%, and 20%), and its combination. The migration of EPCs was assessed using a Boyden chamber assay. Ramiprilat and hUCB-MSCs-derived secretome at all doses increase EPCs migration in dose-dependent manner. Combination of hUCB-MSCs-derived secretome at dose 10% and 20% and ramiprilat significantly increase migrated cells compared to ramiprilat only and secretome only group (p<0.001). In conclusion, hUCB-MSCs-derived secretome and ramiprilat enhance EPCs migration and combination of those two substances furtherly increased the migrated cells. hUCB-MSCs-derived secretome has the potential as regenerative treatment for CAD patients.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Proceedings of the 2020 7th International Conference on Biomedical and Bioinformatics Engineering

自引率

0.00%

发文量